Rating Change
Leerink Partners analysts reiterated a Outperform rating on ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) on June 25, 2026.
reiterateNASDAQ:SPRY
Leerink Partners Reiterates Outperform Rating on ARS Pharmaceuticals, Inc. (SPRY)
Rating Change Leerink Partners analysts reiterated a Outperform rating on ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) on June 25, 2026. Market Context ARS Pharmaceuticals, Inc.
Market Context
ARS Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $8.02 with a market capitalization of $1.1B.
Analyst coverage from Leerink Partners provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for ARS Pharmaceuticals, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for ARS Pharmaceuticals, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jun 25, 2026 | Leerink Partners | Outperform | N/A |
| May 28, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Sep 04, 2025 | Roth Capital | Buy | N/A |
| Mar 07, 2025 | Scotiabank | Sector Outperform | N/A |
| Jan 14, 2025 | Raymond James | Strong Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View SPRY Stock Page
Frequently Asked Questions
What does a Outperform rating mean for SPRY?
A Outperform rating from Leerink Partners reflects the analyst's outlook on ARS Pharmaceuticals, Inc. (NASDAQ:SPRY). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the SPRY forecast page.